CABA earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -1.40. Updated 2026-07-23.
Cabaletta Bio (CABA) Research Hub
Cabaletta Bio (CABA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.35 USD (-8.16%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.40, market cap 0.44B. This hub links to the full technical, earnings and options research available for CABA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.35 USD (-8.16%) |
| 52-week range | 1.32 USD – 3.75 USD |
| Trend regime | Range |
| 14-day RSI | 18.7 (Oversold) |
| Trailing P/E | -1.40 |
| Market cap | 0.44B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CABA
Covered Call on CABA: how it works, illustrative setup around the real 1.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CABA: how it works, illustrative setup around the real 1.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CABA: how it works, illustrative setup around the real 1.35 USD price, max profit/loss, breakeven and when to use it. Educational.
CABA technical analysis: range, last 1.35 USD, RSI 18.7, 52w range 1.32 USD–3.75 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CABA in?
Cabaletta Bio (CABA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CABA in an uptrend or downtrend?
As of 2026-10-26, CABA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CABA's trailing P/E ratio?
CABA's trailing P/E is -1.40, with a market cap of 0.44B. See the earnings research page for full valuation detail.
When does CABA next report earnings?
CABA is next scheduled to report earnings on 2026-08-06.